Quercetin glycosides showed optimum binding affinity with angiotensin-converting-enzyme (−8.5 kcal mol−1) as compared to enalapril (−7.0 kcal mol−1), thereby indicating the role of quercetin glycosides as a potential candidate to treat hypertension, myocardial infarction, and congestive heart failure [38]. The gene discussed is ACE; the disease is myocardial infarction.